MedTrace Logo

Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study

NCT07018401 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 62

Last updated 2025-09-23

No results posted yet for this study

Summary

This is a multicenter U.S. longitudinal study evaluating patients with hereditary hemorrhagic telangiectasia who participated in the PATH-HHT clinical trial of pomalidomide for the treatment of HHT. This study is a longitudinal assessment of safety and effectiveness of pomalidomide in HHT in clinical trial participants following completion of the double-blind, placebo-controlled study.

Conditions

  • Hereditary Hemorrhagic Telangiectasia (HHT)

Interventions

DRUG

Pomalidomide

Oral pomalidomide up to 4 mg daily

Sponsors & Collaborators

Principal Investigators

  • Ellen Zhang, MD · Stanford University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2025-04-08
Completion
2026-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07018401 on ClinicalTrials.gov